IN2014MN02090A - - Google Patents
Info
- Publication number
- IN2014MN02090A IN2014MN02090A IN2090MUN2014A IN2014MN02090A IN 2014MN02090 A IN2014MN02090 A IN 2014MN02090A IN 2090MUN2014 A IN2090MUN2014 A IN 2090MUN2014A IN 2014MN02090 A IN2014MN02090 A IN 2014MN02090A
- Authority
- IN
- India
- Prior art keywords
- brain
- medicine
- anesthetic
- alleviate
- prevent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The purpose of the present invention is to provide a general anesthetic medicine which can prevent and/or alleviate an anesthetic induced neuropathy in the brain (preferably the developing brain). The present invention relates to a medicine which can prevent and/or alleviate an anesthetic induced neuropathy in the brain (preferably the developing brain) said medicine comprising a combination of a general anesthetic drug and hydrogen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012125535 | 2012-05-31 | ||
PCT/JP2013/065094 WO2013180240A1 (en) | 2012-05-31 | 2013-05-30 | Medicine comprising combination of general anesthetic drug and hydrogen |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02090A true IN2014MN02090A (en) | 2015-09-04 |
Family
ID=49673427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2090MUN2014 IN2014MN02090A (en) | 2012-05-31 | 2013-05-30 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150079197A1 (en) |
EP (1) | EP2857026A4 (en) |
JP (1) | JP6168420B2 (en) |
KR (1) | KR20150018832A (en) |
CN (1) | CN104394873A (en) |
AU (1) | AU2013268366A1 (en) |
BR (1) | BR112014029260A2 (en) |
CA (1) | CA2874579A1 (en) |
HK (1) | HK1205450A1 (en) |
IL (1) | IL235718A0 (en) |
IN (1) | IN2014MN02090A (en) |
MX (1) | MX2014014543A (en) |
NZ (1) | NZ701553A (en) |
RU (1) | RU2014152690A (en) |
SG (1) | SG11201407489TA (en) |
WO (1) | WO2013180240A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6253029B2 (en) * | 2015-01-21 | 2017-12-27 | 大陽日酸株式会社 | Anesthesia mounting kit |
US20180338995A1 (en) * | 2017-05-23 | 2018-11-29 | Perricone Hydrogen Water Company, Llc | Systems and methods for treatments using hydrogen and/or noble gases |
US11129848B2 (en) * | 2017-08-08 | 2021-09-28 | Perricone Hydrogen Water Company, Llc | Medication enhancement using hydrogen |
EP3814502A4 (en) * | 2018-06-29 | 2022-10-05 | John Mansell | Compositions and methods for the treatment of anesthesia-induced neurotoxicity |
US11123365B2 (en) | 2019-11-18 | 2021-09-21 | Perricone Hydrogen Water Company, Llc | Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof |
JP7019910B2 (en) * | 2020-07-21 | 2022-02-16 | MiZ株式会社 | Compositions for preventing and / or ameliorating side effects of a drug, symptoms associated with the side effects of a drug, and / or side effects associated with treatment. |
CN117861037A (en) * | 2022-10-11 | 2024-04-12 | 上海氢医医疗科技有限公司 | Hydrogen inhalation treatment of autism |
-
2013
- 2013-05-30 BR BR112014029260A patent/BR112014029260A2/en not_active Application Discontinuation
- 2013-05-30 IN IN2090MUN2014 patent/IN2014MN02090A/en unknown
- 2013-05-30 NZ NZ701553A patent/NZ701553A/en not_active IP Right Cessation
- 2013-05-30 MX MX2014014543A patent/MX2014014543A/en unknown
- 2013-05-30 CN CN201380028933.5A patent/CN104394873A/en active Pending
- 2013-05-30 EP EP13796554.7A patent/EP2857026A4/en not_active Withdrawn
- 2013-05-30 CA CA2874579A patent/CA2874579A1/en not_active Abandoned
- 2013-05-30 JP JP2014518736A patent/JP6168420B2/en not_active Expired - Fee Related
- 2013-05-30 WO PCT/JP2013/065094 patent/WO2013180240A1/en active Application Filing
- 2013-05-30 KR KR20147035945A patent/KR20150018832A/en active Search and Examination
- 2013-05-30 SG SG11201407489TA patent/SG11201407489TA/en unknown
- 2013-05-30 US US14/397,229 patent/US20150079197A1/en not_active Abandoned
- 2013-05-30 AU AU2013268366A patent/AU2013268366A1/en not_active Abandoned
- 2013-05-30 RU RU2014152690A patent/RU2014152690A/en unknown
-
2014
- 2014-11-16 IL IL235718A patent/IL235718A0/en unknown
-
2015
- 2015-04-16 HK HK15103729.5A patent/HK1205450A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2857026A1 (en) | 2015-04-08 |
CA2874579A1 (en) | 2013-12-05 |
SG11201407489TA (en) | 2014-12-30 |
BR112014029260A2 (en) | 2017-06-27 |
HK1205450A1 (en) | 2015-12-18 |
JP6168420B2 (en) | 2017-07-26 |
RU2014152690A (en) | 2016-07-20 |
AU2013268366A1 (en) | 2015-03-19 |
JPWO2013180240A1 (en) | 2016-01-21 |
CN104394873A (en) | 2015-03-04 |
NZ701553A (en) | 2016-06-24 |
EP2857026A4 (en) | 2015-11-04 |
MX2014014543A (en) | 2015-06-05 |
IL235718A0 (en) | 2015-01-29 |
WO2013180240A1 (en) | 2013-12-05 |
US20150079197A1 (en) | 2015-03-19 |
KR20150018832A (en) | 2015-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02090A (en) | ||
MX2015002292A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. | |
EA201991484A1 (en) | MEDICINAL FORMS OF ENZALUTAMIDE | |
AU349827S (en) | Respirator mask | |
IN2015DN03029A (en) | ||
IN2015DN03219A (en) | ||
PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
AU349826S (en) | Cushion for respirator mask | |
MX356728B (en) | Pharmaceutical combination for use in the treatment of diabetes type 2. | |
EA201591679A1 (en) | METHOD OF NON-TOXIC TREATMENT OF ABSTINENT, CAUSED BY MEDICINE | |
HK1208830A1 (en) | Drug delivery device for the treatment of patients with respiratory diseases | |
PH12016501965A1 (en) | S1p modulator immediate release dosage regimen | |
IN2015DN00515A (en) | ||
AU352986S (en) | Nasal dilation device | |
PL2874600T3 (en) | Pharmaceutical composition for the treatment of croakiness and sore throat | |
ECSP12012126A (en) | MEDICINE | |
EA201691108A1 (en) | Quinazoline-THF-Amines as PDE1 Inhibitors | |
MX2015013755A (en) | Pharmaceutical formulation for use in the treatment and/or prevention of restenosis. | |
BR112015005268A2 (en) | syringe containing a composition, in particular pharmaceutical, composed of immunoglobulins, their method of manufacture and their use | |
PH12017500923A1 (en) | New dosage and use of a a2a antagonist | |
MX2014012535A (en) | Combination therapy of anti-mif antibodies and chemotherapeutics. | |
MX365192B (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
MX2016007947A (en) | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features. | |
MX356052B (en) | Synergistic therapies of cannabidiol with hypothermia for neuroprotection. | |
IN2014KN01772A (en) |